USPH Reports Second Quarter 2026 Results, Reaffirms Full Year Guidance

(Moderate)

(Neutral)

Key Terms

gaap financial

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

non-gaap financial

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

redeemable noncontrolling interests financial

A redeemable noncontrolling interest is a minority ownership stake in a company that the holder can force the company to buy back at a set price or under certain conditions. For investors this matters because it creates a future cash obligation and can be treated more like a liability than permanent equity, affecting a company’s reported debt, net income and valuation — think of it as a part-owner who can cash out, forcing the business to pay them.

adjusted ebitda financial

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/05/2026 - 04:25 PM

HOUSTON--(BUSINESS WIRE)-- U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), today reported results for the three and six months ended June 30, 2026.

Total net revenue of $214.1 million for the second quarter ended June 30, 2026 (“Q2 2026”), an 8.5% increase over the second quarter ended June 30, 2025 (“Q2 2025”).
Net income attributable to USPH shareholders of $9.9 million for Q2 2026 compared to $12.4 million for Q2 2025 with earnings per share of $0.25 compared to earnings per share of $0.58 for the same periods, respectively. Under GAAP, changes in the value of redeemable noncontrolling interests, representing our partners’ ownership stakes in subsidiaries not fully owned by USPH, are excluded from net income but are included in the calculation of earnings per share. Improving performance increases the value of these ownership interests, which has a dilutive effect on earnings per share.
Operating results ⁽¹⁾, a non-GAAP measure, of $11.3 million for Q2 2026 compared to $12.4 million for Q2 2025, with operating results per share of $0.75 compared to $0.81 for the same periods, respectively.
Adjusted EBITDA ⁽¹⁾, a non-GAAP measure, of $27.0 million for Q2 2026 compared to $26.9 million for Q2 2025.

_________________
(1)	These are non-GAAP measures. Please refer to the section titled “Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure” for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure.

Chris Reading, Chairman and Chief Executive Officer commented, “Our second quarter 2026 results include an important milestone for USPH as we completed the integration of 31 existing clinics into our hospital affiliations. The remaining 39 hospital affiliated clinics are expected to integrate in the third quarter, resulting in increasing physical therapy revenues and margins. Combined with the partial virtualization of front desk processes and expansion of cash-based programs in our largest partnerships, we expect to accelerate our year over year adjusted EBITDA improvement in the back half of 2026, and for these initiatives to propel us into 2027.”

Mr. Reading continued, “I want to thank our partners, clinical and support staff for their ongoing work, with special callout to those working directly on our hospital initiative. Their work is building momentum for 2027 with an expanding pipeline of opportunities around the country.”

Q2 2026 versus Q2 2025

Physical therapy net revenue was $182.4 million for Q2 2026, an 8.4% increase versus Q2 2025, including a 3.5% increase in mature revenue ⁽¹⁾.
Patient visits ⁽¹⁾ were 1,661,694 for Q2 2026, a 6.6% increase versus Q2 2025, with average daily visits per clinic ⁽¹⁾ of 33.5 for Q2 2026 compared to 32.7 for Q2 2025.
Physical therapy net revenue per patient visit ⁽¹⁾ was $107.59 for Q2 2026, a $2.26 increase compared to Q2 2025.
Physical therapy margin was 19.5% for Q2 2026 compared to 21.2% for Q2 2025. Adjusted physical therapy margin ⁽²⁾ was 19.9% compared to 21.4% for Q2 2025. Q2 2026 results included an unfavorable impact of company-provided health benefit costs compared to a favorable impact in Q2 2025, impacting margins by approximately 100 basis points.
IIP revenue was $31.7 million for Q2 2026, a 9.1% increase compared to Q2 2025. Excluding the IIP acquisition on January 31, 2026, IIP revenue increased 3.6% over the comparable periods.
IIP margin was 20.4% for Q2 2026 compared to 20.3% for Q2 2025.
Corporate expense as a percentage of total revenue was 8.9% in each of Q2 2026 and Q2 2025. Adjusted corporate expense ⁽²⁾as a percentage of total revenue was 8.4% in Q2 2026 and 8.7% in Q2 2025.
The Company added four and closed four locations during Q2 2026, bringing the clinic count ⁽¹⁾ to 781 as of June 30, 2026.

Six Months ended June 30, 2026 versus Six Months ended June 30, 2025

Total net revenue was $412.3 million for year-to-date June 30, 2026 (“YTD 2026”), an 8.2% increase over the year-to-date ended June 30, 2025 (“YTD 2025”).
Physical therapy net revenue was $350.0 million for YTD 2026, a 7.8% increase versus YTD 2025, including a 3.1% increase in mature revenue ⁽¹⁾.
Patient visits ⁽¹⁾ were 3,204,838 for the YTD 2026, a 6.7% increase versus YTD 2025, with average daily visits per clinic ⁽¹⁾ of 32.7 for YTD 2026 compared to 31.9 for the YTD 2025.
Physical therapy net revenue per patient visit ⁽¹⁾ was $107.06 for YTD 2026, a $1.57 increase compared to YTD 2025.
Physical therapy margin was 17.7% for YTD 2026 compared to 19.0% for YTD 2025. Adjusted physical therapy margin ⁽²⁾ was 18.1% compared to 19.2% for YTD 2025.
IIP revenue was $62.3 million for YTD 2026, a 10.4% increase compared to YTD 2025. Excluding the IIP acquisition made on January 31, 2026, IIP revenue increased 5.8% over the comparable periods.
IIP margin was 20.4% for YTD 2026 compared to 19.5% for YTD 2025.
Corporate expense as a percentage of total revenue was 9.0% for YTD 2026 and 8.8% for YTD 2025. Adjusted corporate expense ⁽²⁾as a percentage of total revenue was 8.6% for YTD 2026 and 8.7% for YTD 2025.
Net income attributable to USPH shareholders of $14.9 million for YTD 2026 compared to $22.3 million for YTD 2025 with earnings per share of $0.13 compared to earnings per share of $1.38 for the same periods, respectively.
Operating results ⁽²⁾, a non-GAAP measure, of $18.2 million for YTD 2026 compared to $19.7 million for YTD 2025, with operating results per share of $1.21 compared to $1.30 for the same periods, respectively.
Adjusted EBITDA ⁽²⁾, a non-GAAP measure, of $47.2 million for YTD 2026 compared to $46.4 million for YTD 2025.

_________________
(1)	See “Glossary of Terms” for the definition.
(2)	These are non-GAAP measures. Please refer to the section titled “Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure” for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure.

BALANCE SHEET AND CASH FLOW

Cash and cash equivalents were $24.9 million as of June 30, 2026 compared to $35.6 million as of December 31, 2025. Borrowings under the Company’s credit facility were $221.0 million as of June 30, 2026, compared to $161.8 million as of December 31, 2025.
As previously announced, on April 14, 2026, the Company closed on a $450.0 million, five-year credit facility that includes a $175.0 million term loan and a $275.0 million revolver with a maturity date of April 14, 2031. This is an increase and extension of the Company’s prior $325.0 million credit facility which was due to expire on June 17, 2027.
The Company’s Board of Directors declared a quarterly dividend of $0.46 which will be payable on September 11, 2026 to shareholders of record on August 21, 2026.
Under the Company’s $25.0 million share repurchase authorization, during Q2 2026, the Company repurchased 306,256 of its own shares on the open market for a total consideration of $19.2 million, at an average share price of $62.80. Including repurchases made in 2025, the Company has repurchased 387,578 shares on the open market for a total consideration of $24.8 million, at an average share price of $63.99.

2026 ACQUISITIONS

The Company has announced three acquisitions during 2026 with a cumulative purchase price of $37.6 million and approximately $27.0 million in cumulative annualized revenue.

On July 1, 2026, the Company acquired a 67% equity interest in a 12-clinic physical therapy practice for a purchase price of $16.4 million. The business currently generates $12.0 million in annual revenue and 112,000 annual visits.
On January 31, 2026, the Company acquired a 70% equity interest in an industrial injury prevention business for a purchase price of $15.0 million. The business currently generates $7.0 million in annual revenue.
On January 2, 2026, the Company acquired a 50% equity interest in an 8-clinic physical therapy practice for a purchase price of $6.2 million. The business currently generates $8.0 million in annual revenue and 66,000 annual visits.

HOSPITAL AFFILIATIONS

The Company’s two previously announced hospital affiliations impact 70 existing USPH clinics.

On February 2, 2026, the Company announced a 10-year strategic alliance between its subsidiary, Metro, and NYU Langone. The integration of the 60 clinics began in Q2 2026 and is expected to conclude in the three months ended September 30, 2026 (“Q3 2026”).
On February 25, 2026, the Company announced a 10-year strategic alliance between its subsidiary in the gulf-coast region and a local hospital system. The integration of the 10 clinics is expected to occur in Q3 2026.

2026 EARNINGS GUIDANCE

Management reaffirmed the Company’s full year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million.

CONFERENCE CALL INFORMATION

U.S. Physical Therapy’s management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on August 6, 2026, to discuss the Company’s financial results for the three and six months ended June 30, 2026. Interested parties may participate in the call by dialing (800) 347-6865 (Primary) or (203) 518-9757 (Alternate) and conference ID of USPHQ226. Please call approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company’s website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 4, 2026, on the Company’s website.

FORWARD-LOOKING STATEMENTS

This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply ;
competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
the impact of a termination of one or more of the Company’s hospital affiliated arrangements, which could have an adverse impact on revenue and the results of operations;
the impact of future public health crises and epidemics/pandemics;
certain of our acquisition agreements contain put-rights related to a future purchase of significant equity interests in our subsidiaries or in a separate company;
the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing, and our ability to operate our business;
changes as the result of government enacted national healthcare reform;
the ability to control variable interest entities for which we do not have a direct ownership;
business and regulatory conditions including federal and state regulations;
governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
revenue and earnings expectations;
contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results;
legal actions, which could subject us to increased operating costs and uninsured liabilities;
general economic conditions, including but not limited to inflationary and recessionary periods;
actual or perceived events involving banking volatility, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations;
our business depends on hiring, training, and retaining qualified employees;
availability and cost of qualified physical therapists;
competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
maintaining adequate internal controls;
use of generative artificial intelligence;
maintaining necessary insurance coverage;
availability, terms, and use of capital; and
weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 27, 2026 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.

GLOSSARY OF TERMS

Mature revenue includes revenues from owned and hospital affiliated clinics as well as homecare which were operational prior to January 1, 2025, and are still operating as of the balance sheet date. This metric excludes other management contracts.

Physical therapy revenue per patient visit is net revenue from owned and hospital affiliated clinics as well as homecare divided by total number of patient visits (defined below) during the periods presented. This metric excludes other management contracts.

Patient visits is the number of unique patient visits at the Company’s owned and hospital affiliated clinics as well as homecare for the periods presented. This metric excludes other management contracts.

Average daily visits per clinic is patient visits at the Company’s owned and hospital affiliated clinics, divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of owned and hospital affiliated clinics in operation during the periods presented. This metric excludes homecare and other management contracts.

Clinic count includes owned and hospital affiliated clinics as well as other management contracts. This metric excludes homecare.

ABOUT U.S. PHYSICAL THERAPY, INC.

Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 796 outpatient physical therapy locations in 45 states. USPH locations provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT PER SHARE DATA)

	Three Months Ended						Six Months Ended
	June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025

Net patient revenue	$	173,224		$	164,183		$	337,552		$	316,730
Hospital affiliation revenue		5,564			-			5,564			-
Other revenue		35,271			33,161			69,228			64,402
Net revenue		214,059			197,344			412,344			381,132
Operating cost
Salaries and related costs		125,404			113,788			244,892			225,037
Rent, supplies, contract labor and other		38,965			34,127			77,417			67,971
Depreciation and amortization		5,621			5,741			11,278			11,281
Provision for credit losses		2,120			1,995			4,124			3,843
Clinic closure costs - lease and other		6			69			(62	)		311
Total operating cost		172,116			155,720			337,649			308,443

Gross profit		41,943			41,624			74,695			72,689

Corporate office costs		19,005			17,476			37,279			33,721
Loss (gain) on change in fair value of contingent earn-out consideration		992			(790	)		2,989			(5,612	)
Operating income		21,946			24,938			34,427			44,580

Other (expense) income
Interest expense, debt and other		(3,213	)		(2,422	)		(6,004	)		(4,701	)
Interest income from investments		29			28			45			52
Change in revaluation of put-right liability		(168	)		(339	)		195			(743	)
Equity in earnings of unconsolidated affiliate		408			401			772			794
Loss on extinguishment of debt		(124	)		-			(124	)		-
Loss on sale of a partnership		-			-			-			(123	)
Other		175			47			305			122
Total other expense		(2,893	)		(2,285	)		(4,811	)		(4,599	)
Income before taxes		19,053			22,653			29,616			39,981

Provision for income taxes		4,155			4,933			6,562			8,793

Net income		14,898			17,720			23,054			31,188

Less: Net income attributable to non-controlling interest:
Redeemable non-controlling interest - temporary equity		(4,080	)		(3,914	)		(6,594	)		(5,926	)
Non-controlling interest - permanent equity		(920	)		(1,413	)		(1,524	)		(2,970	)
		(5,000	)		(5,327	)		(8,118	)		(8,896	)

Net income attributable to USPH shareholders	$	9,898		$	12,393		$	14,936		$	22,292

Basic and diluted earnings per share attributable to USPH shareholders⁽¹⁾	$	0.25		$	0.58		$	0.13		$	1.38

Shares used in computation - basic and diluted		15,070			15,197			15,118			15,165

Dividends declared per common share	$	0.46		$	0.45		$	0.92		$	0.90

_________________
(1)	These are non-GAAP measures. Please refer to the section titled “Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure” section of this press release for the calculation of basic and diluted earnings per share.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (IN THOUSANDS)

	Three Months Ended						Six Months Ended
	June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025

Net income	$	14,898		$	17,720		$	23,054		$	31,188
Other comprehensive gain (loss):
Unrealized gain (loss) on cash flow hedge		94			(798	)		454			(2,129	)
Tax effect at statutory rate (federal and state)		(25	)		204			(121	)		544
Comprehensive income	$	14,967		$	17,126		$	23,387		$	29,603

Comprehensive income attributable to non-controlling interest		(5,000	)		(5,327	)		(8,118	)		(8,896	)
Comprehensive income attributable to USPH shareholders	$	9,967		$	11,799		$	15,269		$	20,707

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES SEGMENT INFORMATION

	Three Months Ended						Variance
	June 30, 2026			June 30, 2025			$			%
	(In thousands, except percentages)
*Physical Therapy Operations*
Net patient revenue	$	173,224		$	164,183		$	9,041		5.5	%
Hospital affiliation revenue		5,564			-			5,564		*
Other revenue ⁽¹⁾		3,567			4,109			(542	)	(13.2	)%
Net revenue		182,355			168,292			14,063		8.4	%
Operating costs ⁽¹⁾⁽²⁾		146,884			132,568			14,316		10.8	%
Gross profit	$	35,471		$	35,724		$	(253	)	(0.7	)%

*IIP*
Net revenue	$	31,704		$	29,052		$	2,652		9.1	%
Operating costs ⁽²⁾		25,232			23,152			2,080		9.0	%
Gross profit	$	6,472		$	5,900		$	572		9.7	%

Financial and operating metrics (not in thousands):
Patient visits ⁽³⁾		1,661,694			1,558,756			102,938		6.6	%
Average daily visits per clinic ⁽³⁾		33.5			32.7			0.8		2.4	%
Physical therapy revenue per patient visit ⁽³⁾	$	107.59		$	105.33		$	2.26		2.1	%
Mature revenue percent change ⁽³⁾		3.5	%		0.2	%
Salaries and related costs, as a percentage of revenue ⁽⁴⁾⁽⁵⁾		57.9	%		56.6	%
Adjusted salaries and related costs, as a percentage of revenue ^(4)(5)(6)		57.5	%		56.4	%
Physical therapy operations gross profit margin ⁽²⁾		19.5	%		21.2	%
Adjusted physical therapy operations gross profit margin ⁽²⁾⁽⁷⁾		19.9	%		21.4	%
IIP gross profit margin		20.4	%		20.3	%

_________________
(1)	Includes revenues and/or costs related to other management contracts.
(2)	Amortization of certain intangible assets was reallocated between physical therapy operations and IIP segments for Q2 2025 amounts to conform with current presentation.
(3)	See Glossary of terms for definition. Reflects the average number of clinic locations (755 and 731) during the current and prior-year periods, respectively.
(4)	Beginning Q2 2026, the Company changed its salaries and related costs metric from cost-per-visit to percentage-of-revenue, which management believes is a more meaningful presentation. For hospital affiliated clinics, salaries and related costs reimbursements by hospital systems are recognized as revenue by USPH, supporting this presentation change. Prior period metrics have been revised to conform to the current presentation
(5)	Includes cost and revenue from physical therapy operations. Excludes costs and revenue from other management contracts.
(6)	Excludes certain incentive costs related to Metro. See the section titled Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure.
(7)	Excludes certain incentive costs related to the Metro acquisition, business acquisition costs and clinic closure costs. See the section titled Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure.
*	Not applicable.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES SEGMENT INFORMATION

	Six Months Ended						Variance
	June 30, 2026			June 30, 2025			$			%
*Physical Therapy Operations*	(In thousands, except percentages)
Revenue related to:
Net patient revenue	$	337,552		$	316,730		$	20,822		6.6	%
Hospital affiliation revenue		5,564			-			5,564		*
Other revenue ⁽¹⁾		6,914			7,970			(1,056	)	(13.2	)%
Total revenue		350,030			324,700			25,330		7.8	%
Operating costs ⁽¹⁾⁽²⁾		288,062			263,017			25,045		9.5	%
Gross profit	$	61,968		$	61,683		$	285		0.5	%

*IIP*
Net revenue	$	62,314		$	56,432		$	5,882		10.4	%
Operating costs ⁽²⁾		49,587			45,426			4,161		9.2	%
Gross profit	$	12,727		$	11,006		$	1,721		15.6	%

Financial and operating metrics (not in thousands):
Patient visits ⁽³⁾		3,204,838			3,002,561			202,277		6.7	%
Average daily visits per clinic ⁽³⁾		32.7			31.9			0.8		2.5	%
Physical therapy revenue per patient visit ⁽³⁾	$	107.06		$	105.49		$	1.57		1.5	%
Mature revenue percent change ⁽³⁾		3.1	%		(0.5	%)
Salaries and related costs, as a percentage of revenue ⁽⁴⁾⁽⁵⁾		58.9	%		58.0	%
Adjusted salaries and related costs, as a percentage of revenue ^(4)(5)(6)		58.6	%		58.0	%
Physical therapy operations gross profit margin⁽²⁾		17.7	%		19.0	%
Adjusted physical therapy operations gross profit margin ⁽²⁾⁽⁷⁾		18.1	%		19.2	%
IIP gross profit margin		20.4	%		19.5	%

_________________
(1)	Includes revenues and/or costs related to other management contracts.
(2)	Amortization of certain intangible assets was reallocated between physical therapy operations and IIP segments for YTD 2025 amounts to conform with current presentation.
(3)	See Glossary of terms for definition. Reflects the average number of clinic locations (753 and 728) during the current and prior-year periods, respectively.
(4)	Beginning Q2 2026, the Company changed its salaries and related costs metric from cost-per-visit to percentage-of-revenue, which management believes is a more meaningful presentation. For hospital affiliated clinics, salaries and related costs reimbursements by hospital systems are recognized as revenue by USPH, supporting this presentation change. Prior period metrics have been revised to conform to the current presentation.
(5)	Includes cost and revenue from physical therapy operations. Excludes costs and revenue from other management contracts.
(6)	Excludes certain incentive costs related to Metro. See the section titled Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure.
(7)	Excludes certain incentive costs related to the Metro acquisition, business acquisition costs and clinic closure costs. See the section titled Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measure.
*	Not applicable.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES SUPPLEMENTAL FINANCIAL AND PERFORMANCE METRICS

*Revenue Metrics*

	Physical Therapy Revenue Per Patient Visit ⁽¹⁾				Patient Visits ⁽¹⁾		Average Visits Per Clinic Per Day ⁽²⁾
	2026		2025		2026	2025	2026	2025

First quarter	$	106.49	$	105.66	1,543,144	1,443,805	31.8	31.2
Second quarter	$	107.59	$	105.33	1,661,694	1,558,756	33.5	32.7
Third quarter			$	105.54		1,554,207		32.2
Fourth quarter			$	106.49		1,593,336		32.7
Year	$	107.06	$	105.76	3,204,838	6,150,104	32.7	32.2

_________________
(1)	See definition of the metrics above in the Glossary of Terms.
(2)	Excludes home-care visits.

*Physical Therapy Locations Roll Forward ⁽¹⁾*

	2026		2025
Number of clinics, beginning of period	778		759
Q1 additions	15		14
Q1 closed or sold	(12	)	(9	)
Number of clinics, end of period	781		764
Q2 additions	4		6
Q2 closed or sold	(4	)	(4	)
Number of clinics, end of period	781		766
Q3 additions			18
Q3 closed or sold			(7	)
Number of clinics, end of period			777
Q4 additions			11
Q4 closed or sold			(10	)
Number of clinics, end of period			778

Year-to-date total additions	19		20
Year-to-date total closed or sold	(16	)	(13	)

_________________
(1)	See “Glossary of Terms” for the definition

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)

	June 30, 2026			December 31, 2025
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	24,887		$	35,570
Patient accounts receivable, less provision for credit losses of $3,824 and $3,775, respectively		69,603			64,249
Accounts receivable - other		28,557			24,087
Other current assets		16,628			16,084
Total current assets		139,675			139,990
Fixed assets:
Furniture and equipment		74,132			67,891
Leasehold improvements		60,397			58,985
Fixed assets, gross		134,529			126,876
Less accumulated depreciation and amortization		(94,095	)		(91,225	)
Fixed assets, net		40,434			35,651
Operating lease right-of-use assets		156,466			144,197
Investment in unconsolidated affiliate		12,712			12,275
Goodwill		716,535			692,392
Other identifiable intangible assets, net		176,547			172,861
Other assets		6,505			6,644
Total assets	$	1,248,874		$	1,204,010

LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST
Current liabilities:
Accounts payable - trade	$	6,917		$	6,059
Accrued expenses		45,424			49,424
Current portion of operating lease liabilities		42,871			42,134
Current portion of term loan and notes payable		4,563			9,865
Other current liabilities		10,134			31,558
Total current liabilities		109,909			139,040
Notes payable, net of current portion		890			417
Revolving facility		46,000			30,500
Term loan, net of current portion and deferred financing costs		168,566			121,677
Deferred taxes		30,998			28,391
Operating lease liabilities, net of current portion		122,899			110,572
Other long-term liabilities		2,954			3,214
Total liabilities		482,216			433,811

Redeemable non-controlling interest - temporary equity		317,491			293,311

Commitments and Contingencies

U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $.01 par value, 20,000,000 shares authorized,
17,526,791 and 17,418,621 shares issued, respectively		175			174
Additional paid-in capital		290,551			285,522
Accumulated other comprehensive gain		1,047			714
Retained earnings		213,361			227,216
Treasury stock at cost, 2,603,117 shares and 2,296,059 shares, respectively		(56,478	)		(37,194	)
Total USPH shareholders’ equity		448,656			476,432
Non-controlling interest - permanent equity		511			456
Total USPH shareholders' equity and non-controlling interest - permanent equity		449,167			476,888
Total liabilities, redeemable non-controlling interest,
USPH shareholders' equity and non-controlling interest - permanent equity	$	1,248,874		$	1,204,010

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)

	Six Months Ended
	June 30, 2026			June 30, 2025
OPERATING ACTIVITIES
Net income including non-controlling interest	$	23,054		$	31,188
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:
Depreciation and amortization		11,935			11,924
Provision for credit losses		4,124			3,843
Equity-based awards compensation expense		5,479			3,888
Amortization of debt issuance costs		212			210
Change in deferred income taxes		5,232			7,279
Change in revaluation of put-right liability		(195	)		743
Change in fair value of contingent earn-out consideration		2,989			(5,612	)
Equity of earnings in unconsolidated affiliate		(772	)		(794	)
Loss on sale of clinics and fixed assets		302			438
Loss on sale of a partnership		-			123
Loss on extinguishment of debt		124			-
Changes in operating assets and liabilities:
Patient accounts receivable, net		(9,047	)		(10,232	)
Accounts receivable - other		(2,962	)		355
Other current and long term assets		74			(4,426	)
Accounts payable and accrued expenses		(1,410	)		(7,914	)
Other long-term liabilities		(961	)		(827	)
Net cash provided by operating activities		38,178			30,186

INVESTING ACTIVITIES
Purchase of fixed assets		(10,737	)		(5,830	)
Purchase of majority interest in businesses, net of cash acquired		(21,133	)		(6,890	)
Purchase of redeemable non-controlling interest, temporary equity		(6,531	)		(8,427	)
Purchase of non controlling interest, permanent equity		(8,973	)		(149	)
Proceeds on sale of non-controlling interest, permanent equity		50			9
Repayment of notes receivable related to sales of redeemable non-controlling interest		396			346
Proceeds on sale of partnership interest - redeemable non-controlling interest, temporary equity		221			15
Distributions from unconsolidated affiliate		335			664
Proceeds on sale of partnership interest, clinics and fixed assets		-			700
Other		165			228
Net cash (used in) investing activities		(46,207	)		(19,334	)

FINANCING ACTIVITIES
Payment of debt issuance costs		(2,214	)		-
Proceeds from revolving facility		153,262			73,500
Payments on revolving facility		(137,762	)		(60,000	)
Distributions to non-controlling interest, permanent and temporary equity		(12,326	)		(10,697	)
Cash dividends paid to shareholders		(13,871	)		(13,678	)
Proceeds from term loan		45,625			-
Payments on term loan		(1,875	)		(5,625	)
Principal payments on notes payable		(617	)		(1,628	)
Payment for taxes related to net settlement of equity awards		(51	)		-
Repurchases of common stock		(19,233	)		-
Payment of contingent consideration		(13,592	)		-
Net cash (used in) financing activities		(2,654	)		(18,128	)

Net (decrease) in cash and cash equivalents		(10,683	)		(7,276	)
Cash and cash equivalents - beginning of period		35,570			41,362
Cash and cash equivalents - end of period	$	24,887		$	34,086

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for:
Income taxes	$	4,769		$	9,833
Interest paid		6,589			4,683
Non-cash investing and financing transactions during the period:
Purchase of businesses - seller financing portion		500			-
Fair market value of initial contingent consideration related to purchase of businesses		-			3,059
Notes payable related to purchase of redeemable non-controlling interest, temporary equity		78			89
Notes receivable related to sale of redeemable non-controlling interest, temporary equity		3,649			660
Notes receivable related to the sale of non-controlling interest, permanent equity		527			29
Offset to notes receivable associated with purchase of redeemable non-controlling interest	$	72		$	254

U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES
TO THE MOST DIRECTLY COMPARABLE GAAP MEASURE

The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. The tables also provide a reconciliation of additional non-GAAP measures to the most comparable GAAP measure. Management believes providing Adjusted EBITDA and Operating Results to investors is useful for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.

Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade, loss on sale of a partnership, other income and related portions for non-controlling interests, and other non-recurring items as applicable.

Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade, any allocations to non-controlling interests, all net of taxes, and other non-recurring items as applicable. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.

Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE (IN THOUSANDS, EXCEPT PERCENTAGES AND PER SHARE DATA)

	Three Months Ended						Six Months Ended
	June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025

*Adjusted EBITDA (a non-GAAP measure)*
Net income attributable to USPH shareholders	$	9,898		$	12,393		$	14,936		$	22,292
Adjustments:
Provision for income taxes		4,155			4,933			6,562			8,793
Depreciation and amortization		5,935			6,057			11,935			11,924
Interest expense, debt and other, net		3,213			2,422			6,004			4,701
Interest income from investments		(29	)		(28	)		(45	)		(52	)
Equity-based awards compensation expense		3,168			2,117			5,479			3,888
Change in revaluation of put-right liability		168			339			(195	)		743
Loss (gain) on change in fair value of contingent earn-out consideration		992			(790	)		2,989			(5,612	)
Clinic closure costs ⁽¹⁾		6			69			(62	)		311
Business acquisition related costs ⁽²⁾		219			320			756			800
ERP implementation costs ⁽³⁾		419			159			727			221
Loss on sale of a partnership		-			-			-			123
Loan amendment costs ⁽⁴⁾		288			-			288			-
Loss on extinguishment of debt ⁽⁴⁾		124			-			124			-
Other income		(175	)		(47	)		(305	)		(122	)
Allocation to non-controlling interests		(1,429	)		(1,081	)		(1,997	)		(1,608	)
	$	26,952		$	26,863		$	47,196		$	46,402

*Operating Results (a non-GAAP measure)*
Net income attributable to USPH shareholders	$	9,898		$	12,393		$	14,936		$	22,292
Adjustments:
Loss (gain) on change in fair value of contingent earn-out consideration		992			(790	)		2,989			(5,612	)
Change in revaluation of put-right liability		168			339			(195	)		743
Clinic closure costs ⁽¹⁾		6			69			150			311
Business acquisition related costs ⁽²⁾		219			320			756			800
ERP implementation costs ⁽³⁾		419			159			727			221
Loss on sale of a partnership		-			-			-			123
Loan amendment costs ⁽⁴⁾		288			-			288			-
Loss on extinguishment of debt ⁽⁴⁾		124			-			124			-
Allocation to non-controlling interest		(355	)		(156	)		(356	)		(118	)
Tax effect at statutory rate (federal and state)		(494	)		16			(1,190	)		903
	$	11,265		$	12,350		$	18,229		$	19,663

Operating Results per share (a non-GAAP measure)	$	0.75		$	0.81		$	1.21		$	1.30

*Earnings per share*
Computation of earnings per share - USPH shareholders:
Net income attributable to USPH shareholders	$	9,898		$	12,393		$	14,936		$	22,292
Charges to retained earnings:							.
Revaluation of redeemable non-controlling interest		(8,294	)		(4,806	)		(17,663	)		(1,903	)
Tax effect at statutory rate (federal and state)		2,202			1,228			4,690			486
	$	3,806		$	8,815		$	1,963		$	20,875

Earnings per share (basic and diluted)	$	0.25		$	0.58		$	0.13		$	1.38

Shares used in computation - basic and diluted		15,070			15,197			15,118			15,165

_________________
(1)	Costs associated with clinic closures during the periods presented and, for purposes of Operating Results, includes accelerated depreciation related to closed clinics.
(2)	Primarily consists of retention bonuses, as well as legal and consulting expenses related to the acquisition of equity interests in certain partnerships and costs associated with entering into hospital affiliation contracts.
(3)	Consists of costs related to a one-time financial and human resources systems upgrade.
(4)	Consists of costs related to the amendment of the Company's credit facility.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES RECONCILIATION OF OTHER NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES

	Three Months Ended June 30, 2026
				Adjustments
	Reported (GAAP)			Clinic Closure Costs ⁽¹⁾		Metro Incentive Costs ⁽²⁾			Business Acquisition Related Costs ⁽³⁾			ERP Implementation Costs ⁽⁴⁾			Amended Credit Facility Costs ⁽⁵⁾			Adjusted (Non-GAAP)
	(in thousands, except percentages)

Segment information - Physical Therapy Operations

Salaries and related costs, clinics ⁽⁶⁾	$	104,563		$	-	$	(816	)	$	-		$	-		$	-		$	103,747
Salaries and related costs as a percentage of revenue ⁽⁶⁾		57.9	%		-		(0.5	%)		-			-			-			57.5	%
Gross profit	$	35,471		$	6	$	816		$	-		$	-		$	-		$	36,293
Gross profit margin		19.5	%	*			0.4	%		-			-			-			19.9	%

Corporate office costs	$	19,005		$	-	$	-		$	(219	)	$	(419	)	$	(288	)	$	18,079
Corporate office costs as a percentage of revenue		8.9	%		-		-			(0.1	%)		(0.2	%)		(0.1	%)		8.4	%

	Three Months Ended June 30, 2025
				Adjustments
	Reported (GAAP)			Clinic Closure Costs ⁽¹⁾		Metro Incentive Costs ⁽²⁾			Business Acquisition Related Costs ⁽³⁾			ERP Implementation Costs ⁽⁴⁾			Amended Credit Facility Costs ⁽⁵⁾			Adjusted (Non-GAAP)
	(in thousands, except percentages)

Segment information - Physical Therapy Operations

Salaries and related costs, clinics ⁽⁶⁾	$	93,877		$	-	$	(229	)	$	-		$	-		$	-		$	93,648
Salaries and related costs as a percentage of revenue ⁽⁶⁾		56.6	%		-		(0.1	%)		-			-			-			56.4	%
Gross profit	$	35,724		$	69	$	229		$	-		$	-		$	-		$	36,022
Gross profit margin		21.2	%	*			0.1	%		-			-			-			21.4	%

Corporate office costs	$	17,476		$	-	$	-		$	(178	)	$	(159	)	$	-		$	17,139
Corporate office costs as a percentage of revenue		8.9	%		-		-			(0.1	%)		(0.1	%)		-			8.7	%

_________________
(1)	These are costs incurred during the period that are associated with closed clinics (owned).
(2)	Certain earnout bonuses and incentive costs related to Metro.
(3)	Includes expenses related to the acquisitions of equity interests in certain partnerships and includes costs associated with entering into hospital affiliated contracts.
(4)	Includes costs related to a one-time financial and human resources systems upgrade.
(5)	Certain fees expensed when entering into the Fourth Amended Credit Facility.
(6)	Excludes revenues and costs related to management contracts.
*	Not meaningful

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES RECONCILIATION OF OTHER NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES

	Six Months Ended June 30, 2026
				Adjustments
	Reported (GAAP)			Clinic Closure Costs ⁽¹⁾			Metro Incentive Costs ⁽²⁾			Business Acquisition Related Costs ⁽³⁾			ERP Implementation Costs ⁽⁴⁾			Amended Credit Facility Costs ⁽⁵⁾			Adjusted (Non-GAAP)
	(in thousands, except percentages)
Segment information - Physical Therapy Operations

Salaries and related costs, clinics ⁽⁶⁾	$	203,888		$	-		$	(1,076	)	$	-		$	-		$	-		$	202,812
Salaries and related costs as a percentage of revenue⁽⁶⁾		58.9	%		-			(0.3	%)		-			-			-			58.6	%
Gross profit	$	61,968		$	150		$	1,076		$	107		$	-		$	-		$	63,301
Gross profit margin		17.7	%	*				0.3	%	*				-			-			18.1	%

Corporate office costs	$	37,279		$	-		$	-		$	(756	)	$	(727	)	$	(288	)	$	35,508
Corporate office costs as a percentage of revenue		9.0	%		-			-			(0.2	%)		(0.2	%)		(0.1	%)		8.6	%


	Six Months Ended June 30, 2025
				Adjustments
	Reported (GAAP)			Clinic Closure Costs ⁽¹⁾			Metro Incentive Costs ⁽²⁾			Business Acquisition Related Costs ⁽³⁾			ERP Implementation Costs ⁽⁴⁾			Amended Credit Facility Costs ⁽⁵⁾			Adjusted (Non-GAAP)
	(in thousands, except percentages)

Segment information - Physical Therapy Operations

Salaries and related costs, clinics ⁽⁶⁾	$	185,676		$	-		$	(294	)	$	-		$	-		$	-		$	185,382
Salaries and related costs as a percentage of revenue ⁽⁶⁾		58.0	%		-			(0.1	%)		-			-			-			58.0	%
Gross profit	$	61,683		$	311		$	294		$	-		$	-		$	-		$	62,288
Gross profit margin		19.0	%		0.1	%		0.1	%		-			-			-			19.2	%

Corporate office costs	$	33,721		$	-		$	-		$	(433	)	$	(221	)	$	-		$	33,067
Corporate office costs as a percentage of revenue		8.8	%		-			-			(0.1	%)		(0.1	%)					8.7	%

_________________
(1)	These are costs incurred during the period that are associated with closed clinics (owned).
(2)	Certain earnout bonuses and incentive costs related to Metro.
(3)	Includes expenses related to the acquisitions of equity interests in certain partnerships and includes costs associated with entering into hospital affiliated contracts.
(4)	Includes costs related to a one-time financial and human resources systems upgrade.
(5)	Certain fees expensed when entering into the Fourth Amended Credit Facility.
(6)	Excludes revenues and costs related to management contracts.
*	Not meaningful.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805033144/en/

U.S. Physical Therapy, Inc.
Jason Curtis, Interim Chief Financial Officer
email: jcurtis@usph.com
Chris Reading, Chief Executive Officer
(713) 297-7000

Three Part Advisors
Joe Noyons
(817) 778-8424

Source: U.S. Physical Therapy, Inc.

USPH Reports Second Quarter 2026 Results, Reaffirms Full Year Guidance

Key Terms

Related Articles